The first phase of the hepatitis C vaccine, known as CLL4, has been approved by the Food and Drug Administration and will be administered to people living with the virus.
The vaccine has also been approved for use in adults in the United States who have had no symptoms of the virus for at least six months.
The vaccine was developed by Sanofi Pasteur and Pfizer and will contain a protein called the HLA-DR1 gene that protects against H. influenzae types 1 and 2.
It will also contain antibodies to the H1N1 coronavirus and antibodies to both coronaviruses.
It’s the second phase of a two-year trial that will begin this week.
This phase will also be conducted in other countries.